Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features
about
Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like propertiesLung cancer incidence in never smokersSingle-walled carbon nanotube-induced mitotic disruptionPotential pulmonary effects of engineered carbon nanotubes: in vitro genotoxic effectsMolecular biology of lung cancerThe biology and treatment of EML4-ALK non-small cell lung cancerMucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar featuresIntegrated Palliative Care and Oncologic Care in Non-Small-Cell Lung CancerRoles of NOTCH1 as a Therapeutic Target and a Biomarker for Lung Cancer: Controversies and PerspectivesMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularMolecular pathology of lung cancer: key to personalized medicine.Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkersEpidermal growth factor receptor in non-small cell lung cancerInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaGenomic aberrations in lung adenocarcinoma in never smokersDNA methylation-based biomarkers for early detection of non-small cell lung cancer: an updateHormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative StudiesNon-small cell lung cancer in never smokers: a clinical entity to be identifiedPulmonary adenocarcinoma: a renewed entity in 2011Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma TreatmentsMET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC CellsLipophilic bisphosphonates plus rapamycin: a deadly combination for KRAS-mutated lung adenocarcinomaProportion and clinical features of never-smokers with non-small cell lung cancerClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKA graph theoretic approach to utilizing protein structure to identify non-random somatic mutations.Applications of computational tools to predict functional SNPs effects in human ErbB genes.EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.Utilizing protein structure to identify non-random somatic mutations.Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate eventsExtraction of human kinase mutations from literature, databases and genotyping studies.Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.Genetic and epigenetic tumor suppressor gene silencing are distinct molecular phenotypes driven by growth promoting mutations in nonsmall cell lung cancer.Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.Clinical relevance of KRAS in human cancers.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularLung cancer in never smokers: molecular profiles and therapeutic implications.Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I diseaseReproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the Nurses' Health Study.Current concepts on the molecular pathology of non-small cell lung carcinoma.
P2860
Q21562142-6B566752-01A3-4203-A163-13F6F8D31012Q23913478-E6B8B6DC-DFDC-4C26-9176-57E81E130222Q23916586-9CA58370-6FDE-4FFC-9B88-C42CD8FCD71EQ23916998-384368A5-F103-4538-9D98-9172D2949D52Q24606677-ED2B6279-FBF3-4B32-9952-0B6657AC5006Q24632625-71C74035-C3B0-4600-98DE-7C2F0B888F56Q24683814-2DF27D99-243A-4F65-A588-A687ADC79E16Q26749199-5BAE143C-9D4C-4A00-B698-AE9C67D5E6C6Q26778550-A613A0EC-B58E-499F-917B-99BAEE763F32Q26828860-EA03E723-28A2-408B-9252-02C2B0698BCAQ27691299-197ACB0A-721F-467C-B99B-90E3E1F55431Q27852227-932C3801-B2C8-4760-9D98-0712ADB8AC2FQ28088636-BD40DA9A-587B-4599-A652-A185A2B384EEQ28303718-3B91A04C-F886-44D9-BD65-FAC9B063B460Q28385032-78DE5B20-599E-4935-AB61-F527C0E85205Q28386334-FEE6A08F-1DB4-4054-8A11-C79A372E1C88Q28392724-7338AE67-BAA5-4C60-AEBC-A40CC7913060Q28393152-8126C1CD-A1F9-4350-BCDF-8933775C5B53Q28395348-B1DCBA79-A694-4130-9A8B-03500B2DA4FAQ28547357-8D02ABA3-A66A-4A64-BE02-7A4C92845AE9Q28551045-DAF00B44-E9AB-4E14-AD1A-4773F179C91BQ28606634-BEC688EA-355C-4C9C-B5FF-20B5AC37DBEBQ29248786-A5C6C37F-9DE0-4081-89D8-6DDA290D90DCQ29615472-AEA42BA3-1FCA-4F3D-AA8C-A320C4FA1F7DQ30360645-CFD71E0A-2FFA-47F4-B8F1-7968CA7AF586Q30380373-E9C6754F-2F22-4B5A-8E1E-A6F25A6B5F08Q30397503-66CE9F8E-7D8C-44C9-920D-1B306CD62226Q30431811-1BEFBF08-121C-4740-A376-FEDA950D4F21Q33384115-52275552-A13F-4658-B1BD-458DF32111EAQ33503919-45754987-BEF1-4FEC-A4B9-49D37E2F732BQ33563803-64916E9C-D5DD-4CAB-A168-8BAC37A45A90Q33633715-317D54D5-198A-476C-8B20-3C08149616FFQ33807653-660C6FCB-E56D-418C-8FDA-67B8AFF1B265Q33897022-77A92B3D-EF54-4F0A-BD39-1A9922094E03Q33959887-2E96B890-0830-408B-948E-F6020F1DBB45Q34159011-627621F2-8CDD-43A5-B649-7DEC3A6BB233Q34177155-5BAADD6B-536D-422D-B996-DAB9209B8D50Q34181641-C6FFE91D-9231-4F7D-8ADE-93F6336917D9Q34185518-AC7B4E5A-3024-4798-88E2-37CAFDDF70E4Q34310062-343A3E00-4D27-4BA7-A97C-C06A50D9D0A3
P2860
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Distinct epidermal growth fact ...... and clinicopathologic features
@ast
Distinct epidermal growth fact ...... and clinicopathologic features
@en
Distinct epidermal growth fact ...... and clinicopathologic features
@nl
type
label
Distinct epidermal growth fact ...... and clinicopathologic features
@ast
Distinct epidermal growth fact ...... and clinicopathologic features
@en
Distinct epidermal growth fact ...... and clinicopathologic features
@nl
prefLabel
Distinct epidermal growth fact ...... and clinicopathologic features
@ast
Distinct epidermal growth fact ...... and clinicopathologic features
@en
Distinct epidermal growth fact ...... and clinicopathologic features
@nl
P2093
P3181
P1476
Distinct epidermal growth fact ...... and clinicopathologic features
@en
P2093
Adi F Gazdar
Elaine Wang
Issan Yee San Tam
John D Minna
Kok Keung Ho
Lap Ping Chung
Luc Girard
Maria P Wong
May C M Wong
Shui Wah Chiu
P304
P3181
P356
10.1158/1078-0432.CCR-05-1981
P407
P577
2006-03-01T00:00:00Z